Monica Valeria Estrada
Monica Valeria Estrada
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection
BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ...
PloS one 11 (6), e0157368, 2016
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ...
Genome medicine 11 (1), 1-20, 2019
Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311, 2017
Assessing tumor infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235, 2017
RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune …
S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ...
Clinical Cancer Research 22 (6), 1499-1509, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ...
Nature communications 7 (1), 10582, 2016
MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation
K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ...
Cell metabolism 26 (4), 633-647. e7, 2017
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerAlpelisib and Letrozole in ER+ Metastatic Breast Cancer
IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ...
Clinical cancer research 23 (1), 26-34, 2017
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast CancerPDK1 Mediates Acquired Resistance to CDK4/6 …
VM Jansen, NE Bhola, JA Bauer, L Formisano, KM Lee, KE Hutchinson, ...
Cancer research 77 (9), 2488-2499, 2017
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, ...
Science translational medicine 8 (334), 334ra53-334ra53, 2016
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ...
JCI insight 3 (24), 2018
Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer
L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ...
Clinical Cancer Research 23 (20), 6138-6150, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and …
B Jovanović, IA Mayer, EL Mayer, VG Abramson, A Bardia, ME Sanders, ...
Clinical Cancer Research 23 (15), 4035-4045, 2017
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ...
Science translational medicine 9 (402), eaai7993, 2017
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial
AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, ...
The Lancet Oncology 22 (6), 883-892, 2021
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
DP Kodack, V Askoxylakis, GB Ferraro, Q Sheng, M Badeaux, S Goel, ...
Science translational medicine 9 (391), eaal4682, 2017
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast CancersHER2-Mediated Tumorigenesis Requires mTORC2
M Morrison Joly, DJ Hicks, B Jones, V Sanchez, MV Estrada, C Young, ...
Cancer research 76 (16), 4752-4764, 2016
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast CancerECM Promotes Resistance to HER2/PI3K Inhibition
AB Hanker, MV Estrada, G Bianchini, PD Moore, J Zhao, F Cheng, ...
Cancer research 77 (12), 3280-3292, 2017
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2T798M HER2 Is Sensitive to …
BN Rexer, R Ghosh, A Narasanna, MV Estrada, A Chakrabarty, Y Song, ...
Clinical Cancer Research 19 (19), 5390-5401, 2013
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2FGFR Signaling Promotes Resistance to Dual HER2 …
AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ...
Clinical Cancer Research 23 (15), 4323-4334, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20